Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 5
2015 2
2016 2
2017 2
2018 1
2019 4
2020 1
2021 1
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Soluble antigen arrays provide increased efficacy and safety over free peptides for tolerogenic immunotherapy.
Firdessa-Fite R, Johnson SN, Bechi Genzano C, Leon MA, Ku A, Ocampo Gonzalez FA, Milner JD, Sestak JO, Berkland C, Creusot RJ. Firdessa-Fite R, et al. Among authors: berkland c. Front Immunol. 2024 Jun 12;15:1258369. doi: 10.3389/fimmu.2024.1258369. eCollection 2024. Front Immunol. 2024. PMID: 38933266 Free PMC article.
We previously showed that multivalent delivery of peptides as soluble antigen arrays (SAgAs) efficiently protects against spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse model. ...
We previously showed that multivalent delivery of peptides as soluble antigen arrays (SAgAs) efficiently protects against spon …
Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells.
Leon MA, Wemlinger SM, Larson NR, Ruffalo JK, Sestak JO, Middaugh CR, Cambier JC, Berkland C. Leon MA, et al. Among authors: berkland c. Mol Pharm. 2019 Apr 1;16(4):1563-1572. doi: 10.1021/acs.molpharmaceut.8b01250. Epub 2019 Feb 25. Mol Pharm. 2019. PMID: 30681867 Free PMC article.
Soluble antigen arrays (SAgAs) represent a novel autoantigen delivery system composed of a linear polymer, hyaluronic acid (HA), displaying multiple copies of conjugated autoantigen. We have previously reported that soluble antigen arrays displaying pr …
Soluble antigen arrays (SAgAs) represent a novel autoantigen delivery system composed of a linear polymer, hyaluronic acid (HA …
Soluble antigen arrays improve the efficacy and safety of peptide-based tolerogenic immunotherapy.
Firdessa-Fite R, Johnson SN, Leon MA, Sestak JO, Berkland C, Creusot RJ. Firdessa-Fite R, et al. Among authors: berkland c. bioRxiv [Preprint]. 2023 May 7:2023.05.05.539161. doi: 10.1101/2023.05.05.539161. bioRxiv. 2023. Update in: Front Immunol. 2024 Jun 12;15:1258369. doi: 10.3389/fimmu.2024.1258369. PMID: 37205572 Free PMC article. Updated. Preprint.
We previously showed that multivalent delivery of peptides as soluble antigen arrays (SAgAs) efficiently protects against spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse model. ...
We previously showed that multivalent delivery of peptides as soluble antigen arrays (SAgAs) efficiently protects against spon …
Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes.
Firdessa-Fite R, Johnson SN, Leon MA, Khosravi-Maharlooei M, Baker RL, Sestak JO, Berkland C, Creusot RJ. Firdessa-Fite R, et al. Among authors: berkland c. Diabetes. 2021 Jun;70(6):1334-1346. doi: 10.2337/db20-0845. Epub 2021 Jan 19. Diabetes. 2021. PMID: 33468513 Free PMC article.
Antigen-specific immunotherapy (ASIT) offers a targeted treatment of autoimmune diseases that selectively inhibits autoreactive lymphocytes, but there remains an unmet need for approaches that address the limited clinical efficacy of ASIT. Soluble antigen arr …
Antigen-specific immunotherapy (ASIT) offers a targeted treatment of autoimmune diseases that selectively inhibits autoreactive lymph …
Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis.
Hartwell BL, Pickens CJ, Leon M, Northrup L, Christopher MA, Griffin JD, Martinez-Becerra F, Berkland C. Hartwell BL, et al. Among authors: berkland c. J Autoimmun. 2018 Sep;93:76-88. doi: 10.1016/j.jaut.2018.06.006. Epub 2018 Jul 13. J Autoimmun. 2018. PMID: 30007842 Free PMC article.
Inducing anergy in B cells may be a particularly potent intervention, as B cells can contribute to autoimmune diseases through multiple mechanisms and offer the potential for direct antigen-specific targeting through the B cell receptor (BCR). Our previous results suggeste …
Inducing anergy in B cells may be a particularly potent intervention, as B cells can contribute to autoimmune diseases through multiple mech …
Antigen-Specific Binding of Multivalent Soluble Antigen Arrays Induces Receptor Clustering and Impedes B Cell Receptor Mediated Signaling.
Hartwell BL, Martinez-Becerra FJ, Chen J, Shinogle H, Sarnowski M, Moore DS, Berkland C. Hartwell BL, et al. Among authors: berkland c. Biomacromolecules. 2016 Mar 14;17(3):710-22. doi: 10.1021/acs.biomac.5b01097. Epub 2016 Feb 5. Biomacromolecules. 2016. PMID: 26771518
A pressing need exists for autoimmune disease therapies that act in an antigen-specific manner while avoiding global immunosuppression. Multivalent soluble antigen arrays (SAgAPLP:LABL), designed to induce tolerance to a specific multiple sclerosis autoantige …
A pressing need exists for autoimmune disease therapies that act in an antigen-specific manner while avoiding global immunosuppressio …
Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells.
Leon MA, Firdessa-Fite R, Ruffalo JK, Pickens CJ, Sestak JO, Creusot RJ, Berkland C. Leon MA, et al. Among authors: berkland c. ACS Chem Biol. 2019 Jul 19;14(7):1436-1448. doi: 10.1021/acschembio.9b00090. Epub 2019 Jul 1. ACS Chem Biol. 2019. PMID: 31260253 Free PMC article.
Current therapies for T1D either treat symptoms or cause global immunosuppression, which leave patients at risk of developing long-term complications or vulnerable to foreign pathogens. Antigen-specific immunotherapies have emerged as a selective approach for autoimmune di …
Current therapies for T1D either treat symptoms or cause global immunosuppression, which leave patients at risk of developing long-term comp …
Linking autoantigen properties to mechanisms of immunity.
Griffin JD, Song JY, Sestak JO, DeKosky BJ, Berkland CJ. Griffin JD, et al. Among authors: berkland cj. Adv Drug Deliv Rev. 2020;165-166:105-116. doi: 10.1016/j.addr.2020.04.005. Epub 2020 Apr 20. Adv Drug Deliv Rev. 2020. PMID: 32325104 Free PMC article. Review.
Antigen-specific immunotherapies (ASIT) present compelling potential for introducing precision to the treatment of autoimmune diseases where nonspecific, global immunosuppression is currently the only treatment option. ...Approved allergen-specific immunotherapies are typi …
Antigen-specific immunotherapies (ASIT) present compelling potential for introducing precision to the treatment of autoimmune disease …
Multivalent nanomaterials: learning from vaccines and progressing to antigen-specific immunotherapies.
Hartwell BL, Antunez L, Sullivan BP, Thati S, Sestak JO, Berkland C. Hartwell BL, et al. Among authors: berkland c. J Pharm Sci. 2015 Feb;104(2):346-61. doi: 10.1002/jps.24273. Epub 2014 Dec 1. J Pharm Sci. 2015. PMID: 25447598 Review.
Additionally, vaccines traditionally codeliver antigen with adjuvant to amplify a robust antigen-specific response. Multivalent nanomaterials have since evolved for applications where immune tolerance is desired, such as autoimmune diseases or allergies. In particul …
Additionally, vaccines traditionally codeliver antigen with adjuvant to amplify a robust antigen-specific response. Multivalen …
Pulmonary Administration of Soluble Antigen Arrays Is Superior to Antigen in Treatment of Experimental Autoimmune Encephalomyelitis.
Kuehl C, Thati S, Sullivan B, Sestak J, Thompson M, Siahaan T, Berkland C. Kuehl C, et al. Among authors: berkland c. J Pharm Sci. 2017 Nov;106(11):3293-3302. doi: 10.1016/j.xphs.2017.06.008. Epub 2017 Jun 15. J Pharm Sci. 2017. PMID: 28625726 Free PMC article.
Applying antigen-specific immunotherapy to mucosal surfaces such as the lungs may engage unique immune response pathways to improve efficacy. Pulmonary delivery of soluble antigen arrays (SAgAs) was explored in mice with experimental autoimmune encephalomyeli …
Applying antigen-specific immunotherapy to mucosal surfaces such as the lungs may engage unique immune response pathways to improve e …
19 results